Study guide
7.3 Pharmacological Modulation: Propranolol, Oxandrolone, Growth Hormone, and Exercise Therapy
Certified Burn Registered Nurse CBRN
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Foundations of Burn Care
1.1 CBRN Exam Format, Eligibility, and BCEN Testing Standards 1.2 Anatomy, Histology, and Barrier Functions of the Skin 1.3 Burn Depth Classification and Jackson's Thermal Wound Zones
2 Chapter 2: Pathophysiology of Burn Injury & Systemic Response
2.1 Cellular Pathophysiology and Capillary Permeability in Burn Shock 2.2 Systemic Inflammatory Response Syndrome (SIRS) and MODS 2.3 Pathophysiology of Supraglottic, Subglottic, and Inhalational Injury 2.4 Cellular Phases of Burn Wound Healing and Scar Pathobiology
3 Chapter 3: Prehospital Triage, Primary Survey & Transfer Criteria
3.1 Initial Assessment, Primary Survey (ABCDEF), and Field Stabilization 3.2 Total Body Surface Area (TBSA) Calculation: Rule of Nines, Lund-Browder, and Palmar Method 3.3 American Burn Association (ABA) Burn Center Referral Criteria and Transport Logistics
4 Chapter 4: Fluid Resuscitation & Hemodynamic Stabilization (<72 Hours)
4.1 Fluid Resuscitation Formulas: Parkland (Baxter), Modified Brooke, and Consensus Protocols 4.2 Resuscitation Endpoints: Urine Output Titration, Base Deficit, and Hemodynamic Monitoring 4.3 Complications of Fluid Creep and Intra-Abdominal Hypertension / Abdominal Compartment Syndrome 4.4 Extremity Compartment Syndrome, Monitoring, and Emergent Escharotomy / Fasciotomy
5 Chapter 5: Airway Management & Inhalation Injury Management
5.1 Upper Airway Compromise, Indications for Early Endotracheal Intubation, and Airway Stabilization 5.2 Lower Airway Chemical Tracheobronchitis, Diagnostic Bronchoscopy, and Lung-Protective Mechanical Ventilation 5.3 Carbon Monoxide (CO) Toxicity, Cyanide Poisoning, and Specific Antidotes (Hydroxocobalamin)
6 Chapter 6: Acute Multisystem Assessment & Critical Care Management
6.1 Cardiovascular Derangements, Myocardial Depression, and Hemodynamic Optimization 6.2 Acute Kidney Injury, Rhabdomyolysis / Myoglobinuria, and Fluid-Electrolyte Shifts 6.3 Gastrointestinal Complications, Ileus, Early Enteral Nutrition, and Curling's Ulcer Prophylaxis 6.4 Neurological Impairment, Anemia of Burn Injury, Coagulopathy, and Musculoskeletal Protection
7 Chapter 7: Hypermetabolism & Nutritional Support
7.1 The Biphasic Metabolic Response: Ebb vs. Flow Phases and Persistent Hypermetabolism 7.2 Indirect Calorimetry, Caloric Equations (Curreri/Toronto), and Micronutrient / Trace Mineral Needs 7.3 Pharmacological Modulation: Propranolol, Oxandrolone, Growth Hormone, and Exercise Therapy 7.4 Stress Hyperglycemia, Intensive Insulin Protocols, and Adrenal / Thyroid Axis Dysregulation
8 Chapter 8: Pain Management in Burn Care
8.1 Pain Classification in Burns: Background, Procedural, Breakthrough, and Chronic Neuropathic Pain 8.2 Multimodal Analgesia: Opioids, Ketamine, Gabapentinoids, NSAIDs, and Regional Anesthesia 8.3 Non-Pharmacological Modalities: Virtual Reality, Cognitive Behavioral Techniques, Hypnosis, and Distraction
9 Chapter 9: Agitation, Delirium & Post-Burn Pruritus
9.1 Agitation Management, Targeted Sedation Protocols (RASS/SAS), and Circadian Rhythm Support 9.2 ICU Delirium: Risk Factors, Screening (CAM-ICU/ICDSC), Non-Pharmacological Bundles, and Medical Management 9.3 Post-Burn Itch: Histaminergic vs. Neuropathic Pruritus, Oral Antihistamines, Gabapentin, and Topical Emollients
10 Chapter 10: Burn Wound Assessment, Topical Antimicrobials & Dressings
10.1 Serial Wound Bed Assessment, Tissue Perfusion, and Documentation Standards 10.2 Topical Antimicrobial Formulations: Silver Sulfadiazine, Mafenide Acetate, Silver Nitrate, and Modern Silver Dressings 10.3 Wound Bed Preparation: Surgical, Enzymatic (Collagenase/Bromelain), Autolytic, and Mechanical Debridement 10.4 Modern Dressings, Hydrogels, Foam Dressings, Negative Pressure Wound Therapy (NPWT), and Moisture Retentive Balances
11 Chapter 11: Surgical Excision, Skin Grafting & Wound Closure
11.1 Principles of Early Tangential vs. Fascial Surgical Excision and Blood Conservation 11.2 Split-Thickness and Full-Thickness Autografting: Mesh Expansion Ratios vs. Sheet Grafts 11.3 Biologic Coverings, Dermal Regeneration Templates (Integra/Novosorb BTM), Allograft, and Xenograft 11.4 Autologous Cell Suspensions (ReCell), Cultured Epithelial Autografts (CEA), and Donor Site Management
12 Chapter 12: Burn Sepsis, Infection Control & Antimicrobial Therapy
12.1 Burn Center Infection Control: Contact Precautions, Hydrotherapy Sanitation, and Environmental Controls 12.2 Differentiating Hypermetabolic SIRS from Burn Sepsis: ABA Consensus Sepsis Criteria 12.3 Common Burn Pathogens (Pseudomonas, MRSA, Acinetobacter, Candida, Aspergillus) and Empiric Coverage 12.4 Invasive Burn Wound Infection: Clinical Signs, Quantitative Biopsy (>10^5 CFU/g), and Histopathological Invasion
13 Chapter 13: Specific Burn Etiologies: Electrical, Chemical & Cold Injuries
13.1 Electrical Burn Injuries: High-Voltage vs. Low-Voltage, Arc/Flash, Cardiac Monitoring, and Deep Muscle Necrosis 13.2 Chemical Injuries: Acids (Coagulation Necrosis), Alkalis (Liquefactive Necrosis), Hydrofluoric Acid (Calcium Gluconate), and Decontamination 13.3 Radiation Burns, Cutaneous Radiation Syndrome, Cold Injuries (Frostbite Triage and Thawing Protocols), and Vasodilator Therapy
14 Chapter 14: Special Burn Populations & Cutaneous Syndromes
14.1 Pediatric Burn Resuscitation (Maintenance Fluids + D5W), Surface Area Dynamics, and Non-Accidental Trauma Screening 14.2 Geriatric Burn Care: Thin Dermis, Altered Fluid Tolerance, Pre-existing Comorbidities, and Mortality Prognostication (Baux Score) 14.3 Burn Injury in Pregnancy: Maternal Physiology, Resuscitation, and Fetal Surveillance 14.4 Severe Cutaneous Adverse Reactions: Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), SCORTEN, and Specialized Burn Unit Nursing 14.5 Necrotizing Soft Tissue Infections and Friction/Shear Injuries
15 Chapter 15: Rehabilitation, Scar Management & Reconstruction
15.1 Anti-Deformity Positioning, Range-of-Motion Exercises, and Custom Splinting Across Major Joints 15.2 Hypertrophic Scarring Mechanisms, Myofibroblasts, and Vancouver Scar Scale (VSS) Assessment 15.3 Custom Pressure Garments (20-30 mmHg), Silicone Sheeting, Fractional CO2 Laser Resurfacing, and Contracture Release 15.4 Psychosocial Recovery, Post-Traumatic Stress Disorder (PTSD), Body Image Adaptation, Peer Support (Phoenix Society), and School/Work Reintegration 15.5 Discharge Teaching, Transition to Ambulatory Care, and Home Management
16 Chapter 16: Professional Practice, Ethics, Quality & Disaster Triage
16.1 Ethical Dilemmas in Burn Critical Care, Surrogate Decision-Making, Futility, and Palliative / End-of-Life Symptom Management 16.2 Interprofessional Burn Team Roles, Multidisciplinary Rounds, Structured Handoffs, and Patient/Family Advocacy 16.3 Burn Quality Improvement, American Burn Association (ABA) Verification Standards, and National Burn Repository (NBR) Benchmarking 16.4 Diversity, Equity, Inclusion, and Intraprofessional Nursing Development 16.5 Community Outreach, Burn Prevention Education, and Home Safety 16.6 Mass Casualty Burn Disasters, Secondary Triage Schemes (ABA/ABLS Triage Matrix), Surge Capacity, and CBRN/HAZMAT Emergency Response
7.3 Pharmacological Modulation: Propranolol, Oxandrolone, Growth Hormone, and Exercise Therapy
Key Takeaways Explain This Topic AI
Pharmacological anti-catabolic therapy is required in severe burns because nutritional support alone cannot overcome the massive 10- to 50-fold catecholamine- and glucocorticoid-driven hypermetabolic state.
Propranolol, a non-selective beta-1 and beta-2 adrenergic antagonist, reduces resting energy expenditure by 15%–25%, lowers cardiac workload, blunts peripheral lipolysis, reverses hepatic steatosis, and preserves lean body mass; it is titrated to reduce baseline resting heart rate by 15% to 20%.
Oxandrolone, an oral synthetic anabolic androgenic steroid with high anabolic activity and minimal androgenicity, significantly accelerates donor site re-epithelialization, preserves lean body mass, and shortens hospital length of stay (standard adult dose: 10 mg PO BID; pediatrics: 0.1 mg/kg PO BID).
Recombinant Human Growth Hormone (rhGH) is effective for linear growth and wound healing in pediatric burns, but is strictly avoided in critically ill adult burn patients due to clinical trial evidence demonstrating doubled mortality from severe hyperglycemia, infection, and multi-organ failure.
Non-pharmacological metabolic interventions—including maintaining an ambient room temperature of 85°F–90°F (29°C–32°C) to eliminate shivering thermogenesis and instituting early progressive resistive exercise therapy—synergize with pharmacotherapy to preserve functional myofibrillar mass.
Last updated: August 2026
7.3 Pharmacological Modulation: Propranolol, Oxandrolone, Growth Hormone, and Exercise Therapy
Core Knowledge: Providing optimal enteral nutrition is essential, but nutritional support alone is insufficient to halt the hypercatabolic storm of severe thermal trauma. Exogenous calories without metabolic modulation often lead to excessive adipose deposition and fatty liver rather than myofibrillar muscle preservation. Pharmacological and environmental modulation blunts hyperadrenergic signaling, suppresses proteolysis, and stimulates net protein synthesis. Certified Burn Registered Nurses (CBRN) play a central role in initiating, titrating, and monitoring anti-catabolic agents including propranolol and oxandrolone , while maintaining thermal neutrality and integrating progressive resistive exercise.
1. Rationale for Anti-Catabolic and Anabolic Pharmacotherapy
In burns ≥ 40 % \ge 40\% ≥ 40% TBSA, the neuroendocrine drive is so intense that skeletal muscle continues to break down even in the presence of massive positive caloric balance. Pharmacological agents target the specific biochemical pathways mediating this catabolic response: PHARMACOLOGICAL & METABOLIC TARGETS IN BURNS
- ┌──────────────────────────────────────────────┬───────────────────────────────────────────┐
- │ Pathophysiological Driver │ Therapeutic Countermeasure │
- ├──────────────────────────────────────────────┼───────────────────────────────────────────┤
- │ Massive Catecholamine Surge (Epi/Norepi) │ PROPRANOLOL (Non-selective β1/β2 Blockade)│
- │ Severe Glucocorticoid Proteolysis & Cachexia │ OXANDROLONE (Synthetic Anabolic Androgen) │
- │ Depressed Linear Growth & Wound Hypoplasia │ RECOMBINANT GROWTH HORMONE (Pediatrics) │
- │ Shivering Thermogenesis & Cold Stress │ THERMONEUTRAL AMBIENT ROOM (85°F–90°F) │
- │ Sarcopenia & Disuse Myofibrillar Atrophy │ PROGRESSIVE RESISTIVE EXERCISE THERAPY │
- └──────────────────────────────────────────────┴───────────────────────────────────────────┘
- 2. Propranolol: Non-Selective Beta-Adrenergic Antagonism
Propranolol is a non-selective beta-1 and beta-2 adrenergic receptor antagonist that acts as the primary pharmacological blunt against the 10- to 50-fold circulating catecholamine flood. MECHANISMS OF PROPRANOLOL IN BURNS
- ┌─────────────────────────────────────────────────────────────────────────────┐
- │ PROPRANOLOL (β1 & β2 Blockade) │
- └──────────────────────────────────────┬──────────────────────────────────────┘
- │
- ┌───────────────────────────────┼───────────────────────────────┐
- ▼ ▼ ▼
- ┌──────────────────────────────┐┌──────────────────────────────┐┌──────────────────────────────┐
- │ CARDIOVASCULAR ││ ADIPOSE TISSUE ││ SKELETAL MUSCLE │
- │ • Decreases resting HR by ││ • Blocks hormone-sensitive ││ • Inhibits intracellular │
- │ 15% to 20% ││ lipase (HSL) ││ proteolytic enzymes │
- │ • Lowers myocardial oxygen ││ • Reduces circulating FFA ││ • Improves net fractional │
- │ consumption (MVO2) ││ flux to liver ││ protein synthesis │
- │ • Decreases overall REE ││ • Reverses hepatic steatosis ││ • Preserves lean body mass │
- │ by 15% to 25% ││ and hepatomegaly ││ and muscle strength │
- └──────────────────────────────┘└──────────────────────────────┘└──────────────────────────────┘
- Clinical Benefits of Propranolol
Reduces Resting Energy Expenditure: Blunts whole-body metabolic rate by 15% to 25% , dramatically lowering caloric demand.
Myocardial Protection: Reduces rate-pressure product and myocardial work without compromising central cardiac output in the flow phase.
Reversal of Hepatic Steatosis: By inhibiting peripheral lipolysis, propranolol shuts off the flood of free fatty acids entering the liver, shrinking fatty liver infiltration and reducing liver size by up to 40% within weeks.
Enhanced Wound Healing: Beta-2 blockade promotes keratinocyte migration and accelerates re-epithelialization of partial-thickness burns and split-thickness donor sites.
Dosing and Nursing Titration
Initiation: Begun during the early flow phase (post-resuscitation, typically >48 to 72 hours post-burn ) once intravascular volume is stabilized and the patient exhibits persistent hyperdynamic tachycardia.
Starting Dose: Adult: 10 to 20 mg PO every 6 to 8 hours (or IV infusion if enteral absorption is erratic); pediatric: 0.5 to 1.0 mg/kg/day divided q6–8h.
Titration Goal: Titrate upward to achieve a 15% to 20% reduction in resting heart rate from baseline (e.g., reducing a resting flow-phase heart rate from 135 bpm down to 105–110 bpm in adults).
Nursing Safety Alerts:
Continuously monitor heart rate and blood pressure prior to each dose.
Hold and notify provider if heart rate drops below 60 bpm in adults (or age-appropriate pediatric threshold) or if MAP < 65 mmHg <65\text{ mmHg} < 65 mmHg .
Caution in patients with reactive airway disease (asthma, severe inhalation injury) due to potential beta-2 bronchospasm.
Never discontinue propranolol abruptly; sudden cessation triggers a rebound adrenergic crisis.
3. Oxandrolone: Synthetic Anabolic Androgenic Steroid
Oxandrolone is an oral synthetic testosterone derivative with modified chemical structure (17-alpha-methylated) that provides high anabolic activity with minimal androgenic side effects (anabolic-to-androgenic ratio of approximately 10:1 to 13:1). OXANDROLONE CLINICAL EFFICACY
- ┌─────────────────────────────────────────────────────────────────────────────┐
- │ OXANDROLONE (10 mg PO BID in Adults) │
- ├─────────────────────────────────────────────────────────────────────────────┤
- │ • Accelerates Donor Site Healing: Shortens time to re-epithelialization │
- │ by 2 to 3 days (p < 0.001), allowing faster re-harvesting of donor sites. │
- │ • Preserves Lean Body Mass (LBM): Increases intracellular protein synthesis │
- │ and decreases urinary nitrogen wasting. │
- │ • Shortens Length of Hospital Stay: Significantly reduces acute burn ICU │
- │ and total hospital days. │
- │ • Promotes Long-Term Weight Gain: Accelerates restoration of functional │
- │ body mass during acute recovery and outpatient rehabilitation. │
- └─────────────────────────────────────────────────────────────────────────────┘
- Dosing, Administration, and Monitoring
Standard Adult Dosing: 10 mg PO twice daily (BID) .
Pediatric Dosing: 0.1 mg/kg PO twice daily (BID) .
Timing: Initiated once the patient enters the flow phase and enteral access is established; frequently continued throughout acute hospitalization and for 6 to 12 months post-discharge during intensive rehabilitation.
Nursing Surveillance & Laboratory Monitoring:
Hepatic Function Tests (LFTs): Baseline and weekly monitoring of AST, ALT, alkaline phosphatase, and total bilirubin. Mild transaminase elevations (2–3x normal) are common; hold therapy if transaminases rise > 5 × >5\times > 5 × upper limit of normal or if clinical jaundice develops.
Virilization Monitoring: Monitor female patients and prepubertal children for signs of androgen excess (hirsutism, acne, clitoromegaly, deepening of the voice).
Fluid Retention: Monitor for peripheral edema in patients with borderline cardiac function.
4. Recombinant Human Growth Hormone (rhGH) & IGF-1
Recombinant human Growth Hormone (rhGH) stimulates the transcription of Insulin-Like Growth Factor 1 (IGF-1) in the liver and peripheral tissues, driving cellular proliferation and amino acid uptake. GROWTH HORMONE IN BURNS: PEDIATRIC VS. ADULT CONTRAST
- ┌────────────────────────────────────────┬────────────────────────────────────────┐
- │ PEDIATRIC BURNS │ CRITICAL ADULT BURNS │
- ├────────────────────────────────────────┼────────────────────────────────────────┤
- │ • Safe and highly effective │ • CONTRAINDICATED / STRICT CAUTION │
- │ • Restores post-burn linear growth │ • Landmark clinical trials proved │
- │ • Accelerates donor site healing │ rhGH DOUBLES MORTALITY in critically │
- │ • Preserves bone mineral density │ ill adults │
- │ • Enhances immune cell function │ • Driven by severe hyperglycemia, │
- │ • Dose: 0.05–0.2 mg/kg/day SubQ │ septic shock, and multi-organ failure│
- └────────────────────────────────────────┴────────────────────────────────────────┘
Caution
Recombinant human Growth Hormone (rhGH) must NEVER be routinely administered to critically ill adult burn patients in the ICU. Multicenter randomized trials demonstrated a 2-fold increase in adult ICU mortality associated with high-dose rhGH, mediated by lethal stress hyperglycemia, impaired neutrophil phagocytosis, and hyperosmolar complications. In adults, oxandrolone is the anabolic agent of choice.
5. Non-Pharmacological Strategies: Thermoneutrality & Resistive Exercise
Pharmacotherapy must be paired with environmental and physical interventions to achieve complete metabolic control. THERMAL AND EXERCISE MODULATION PROTOCOLS
- ┌─────────────────────────────────────────────────────────────────────────────┐
- │ 1. THERMONEUTRAL AMBIENT ENVIRONMENT: │
- │ • Ambient Burn Room Temperature Target: 85°F to 90°F (29°C to 32°C) │
- │ • Relative Humidity Target: 40% to 50% │
- │ • Rationale: Eliminates evaporative cooling and shivering thermogenesis, │
- │ which otherwise spikes metabolic rate and VO2 by an additional 50–100%.│
- ├─────────────────────────────────────────────────────────────────────────────┤
- │ 2. PROGRESSIVE RESISTIVE EXERCISE TRAINING (PRET): │
- │ • Initiate early in ICU stay as soon as grafts are adherent (Post-op 4–7)│
- │ • Combines resistive load training (bands/weights) with aerobic cycling. │
- │ • Cellular Effect: Mechanotransduction stimulates myofibrillar protein │
- │ synthesis, directing ingested amino acids into functional muscle mass │
- │ rather than visceral fat. │
- └─────────────────────────────────────────────────────────────────────────────┘